Iruplinalkib (WX­0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.

Yang, Yingying; Zheng, Qingmei; Wang, Xinmei; Zhao, Shuyong; Huang, Wenshu; Jia, Linchao; Ma, Cuicui; Liu, Shicong; Zhang, Yongpeng; Xin, Qianqian; Sun, Yan; Zheng, Shansong

Iruplinalkib (WX0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.

Yang, Yingying; Zheng, Qingmei; Wang, Xinmei; Zhao, Shuyong; Huang, Wenshu; Jia, Linchao; Ma, Cuicui; Liu, Shicong; Zhang, Yongpeng; Xin, Qianqian; Sun, Yan; Zheng, Shansong.

Afiliación

Yang Y; Department of Nonclinical Development, Qilu Pharmaceutical Co., Ltd., Jinan, 250104, China.
Zheng Q; Department of Nonclinical Development, Qilu Pharmaceutical Co., Ltd., Jinan, 250104, China.
Wang X; Department of Nonclinical Development, Qilu Pharmaceutical Co., Ltd., Jinan, 250104, China.
Zhao S; Department of Nonclinical Development, Qilu Pharmaceutical Co., Ltd., Jinan, 250104, China.
Huang W; Department of Nonclinical Development, Qilu Pharmaceutical Co., Ltd., Jinan, 250104, China.
Jia L; Department of Nonclinical Development, Qilu Pharmaceutical Co., Ltd., Jinan, 250104, China.
Ma C; Department of Nonclinical Development, Qilu Pharmaceutical Co., Ltd., Jinan, 250104, China.
Liu S; Department of Nonclinical Development, Qilu Pharmaceutical Co., Ltd., Jinan, 250104, China.
Zhang Y; Department of Nonclinical Development, Qilu Pharmaceutical Co., Ltd., Jinan, 250104, China.
Xin Q; Department of Nonclinical Development, Qilu Pharmaceutical Co., Ltd., Jinan, 250104, China.
Sun Y; Department of Clinical Development, Qilu Pharmaceutical Co., Ltd., Jinan, 250104, China.
Zheng S; Department of Clinical Pharmacology, Qilu Pharmaceutical Co., Ltd., 8888 Lvyou Road, High-tech Zone, Jinan, 250104, China. shansong.zheng@qilu-pharma.com.

Invest New Drugs ; 41(2): 254-266, 2023 04.

Article en En | MEDLINE | ID: mdl-37036582

Asunto(s)

Carcinoma de Pulmón de Células no Pequeñas; Neoplasias Pulmonares; Humanos; Animales; Ratones; Carcinoma de Pulmón de Células no Pequeñas/patología; Crizotinib/farmacología; Crizotinib/uso terapéutico; Inhibidores de Proteínas Quinasas/farmacología; Inhibidores de Proteínas Quinasas/uso terapéutico; Proteínas Tirosina Quinasas; Receptores ErbB/genética; Neoplasias Pulmonares/patología; Ratones Desnudos; Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2; Células HEK293; Proteínas Tirosina Quinasas Receptoras; Quinasa de Linfoma Anaplásico/metabolismo; Resistencia a Antineoplásicos; Piridinas/uso terapéutico; Mutación; Línea Celular Tumoral; Proteínas Proto-Oncogénicas; Proteínas de Neoplasias/metabolismo; Oncogenes

Palabras clave

Anaplastic lymphoma kinase; Crizotinib resistance; Iruplinalkib; Non-small cell lung cancer; Resistance mechanisms; Tyrosine kinase inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Invest New Drugs Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google